NOVALUNG CONSOLE (LINUX BOARD)
Received May 2, 2025 · Event occurred Apr 2, 2025
Report 3002807005-2025-00033 · MDR key 21953155
Device
Generic name
Extextracorporeal System For Long-term Respiratory / Cardiopulmonary Failure
Manufacturer
St. Wendel AgCatalog number
F30000162
Product problems
- Device Alarm System
- Communication or Transmission Problem
- Protective Measures Problem
- Device Alarm System
- Communication or Transmission Problem
- Protective Measures Problem
Patient
NA · Unknown
- No Clinical Signs, Symptoms or Conditions
- No Clinical Signs, Symptoms or Conditions
Narrative
Description of Event or Problem
A USER FACILITY REPORTED THAT DURING EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT, THE FLOW MEASUREMENT STOPPED AND THE CONSOLE DISPLAYED ERROR #208. THE PATIENT WAS TRANSFERRED TO ANOTHER NOVALUNG CONSOLE WITHOUT COMPLICATION OR BLOOD LOSS. THERE WAS NO INDICATION OF RESULTING PATIENT SERIOUS INJURY. THE COMPLAINT SAMPLE WAS RECEIVED BY XENIOS FOR PRODUCT EVALUATION.
Additional Manufacturer Narrative
ADDITIONAL INFORMATION: B5, D9, H3 NON-CONFORMITY WAS NOT OBSERVED DURING THE MANUFACTURING PROCESS. THE COMPLAINT SAMPLE AND CONSOLE LOGFILES WERE RECEIVED BY XENIOS FOR PRODUCT EVALUATION. VISUAL INSPECTION AND TESTING OF THE SENSOR INTERFACE/CONNECTIONS SHOWED THAT THEY WERE CORRECTLY INSTALLED AND THERE WERE NO DEFECTS AT THE SOLDER JOINTS. ADDITIONALLY, THE SIGNALS OF THE SENSOR CONNECTION INTERFACE SHOWED CORRECT TRANSMISSION. FUNCTIONAL TESTING OF THE SENSOR BOX WAS PERFORMED IN A FOUR-DAY ENDURANCE TEST, DURING WHICH THE SENSOR BOX WAS MOUNTED ON A COMPACT HOLDER, AND NO ERRORS OCCURRED. THE REPORTED ALARM COULD NOT BE REPRODUCED DURING FUNCTIONAL TESTING.
Additional Manufacturer Narrative
THE PLANT INVESTIGATION IS IN PROCESS. A SUPPLEMENTAL MDR WILL BE SUBMITTED UPON COMPLETION OF THIS ACTIVITY.
Description of Event or Problem
A USER FACILITY REPORTED THAT DURING EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT, THE FLOW MEASUREMENT STOPPED AND THE CONSOLE DISPLAYED ERROR #208. THE PATIENT WAS TRANSFERRED TO ANOTHER NOVALUNG CONSOLE WITHOUT COMPLICATION OR BLOOD LOSS. THERE WAS NO INDICATION OF RESULTING PATIENT SERIOUS INJURY. THE COMPLAINT SAMPLE WAS AVAILABLE FOR PRODUCT EVALUATION.